Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters’ Levels, but Has No Effect on Body Composition Parameters

BACKGROUND: Psoriasis is frequently accompanied by metabolic syndrome. Effect of anti-tumor necrosis factor therapies on increases in body weight well-known. Data the effects interleukin-17 inhibitors are limited. Authors determined effect anti-interleukin-17 composition and serum lipid inflammatory parameters among severe psoriatic patients. METHODS: Thirty-five patients were enrolled. Twenty-two received secukinumab 13 ixekizumab as their 2nd-or 3rd-line biological treatment. Before treatment initiation 6 months later, laboratory examinations measuring panels analyses performed. RESULTS: After months, a significant reduction was observed psoriasis area severity index (p < 0.001) from 18 to 0, c-reactive protein 6.6 4.00 mg/L, low-density lipoprotein-cholesterol = 0.004) 3.69 3.19 mmol/L, an improvement high-density 0.022) 1.31 1.40 mmol/L. Median baseline mass 32.80 kg/m2. The did not show any changes. CONCLUSIONS: Anti-interleukin-17 therapy does cause changes parameters. Improvements might have beneficial patients’ cardiometabolic status. This be detectable high-risk obese